Mumbai, Jan. 28 -- Aurobindo Pharma announced that the United States Food and Drug Administration (US FDA) inspected Unit-2, an API manufacturing facility,

of Apitoria Pharma, a wholly owned subsidiary of the Company, situated at Gaddapotharam Village IDA, Jinnaram Mandal, Sanga Reddy District, Telangana from 23 September to 27 September 2024. The Unit has now received an Establishment Inspection Report (EIR) classifying the facility as Voluntary Action Indicated (VAI).

Published by HT Digital Content Services with permission from Capital Market....